Apoptosis in vascular disease

Thrombosis and Haemostasis

Volumn 82, Issue 2, 1999, Pages 727-735

  Freyssinet, Jean Marie ^a,b   Toti, Florence ^a,b   Hugel, Bénédicte ^a,b   Gidon Jeangirard, Carole ^a,b   Kunzelmann, Corinne ^a,b   Martínez, M Carmen ^a,b   Meyer, Dominique ^b  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLSERINE;

APOPTOSIS; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; HUMAN; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; VASCULAR DISEASE;

EID: 0032718666     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615904     Document Type: Conference Paper

References (84)

1. Kerr J, Wyllie A, Currie A. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26:239-257.
2. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267:1456-1462.
3. Jacobson MD, Weil M, Raff MC. Programmed cell death in animal development. Cell. 1997;88:347-354.
4. Evan G, Littlewood T. A matter of life and cell death. Science. 1998;281:1317-1322.
5. Ellis RE, Yuan J, Horvitz HR. Mechanisms and functions of cell death. Annu Rev Cell Biol. 1991;663-698.
6. Boise LH, Thompson CB. Hierarchical control of lymphocyte survival. Science. 1996;274:67,68.
7. Majno G, Joris I. Apoptosis, oncogenesis, and necrosis. An overview of cell death. Am J Pathol. 1995;146: 3-15.
8. Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature. 1998;391:43-50.
9. Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol. 1992;148:2207-2216.
10. Martin SJ, Reutelingsperger CPM, McGahon AJ, Rader JA, van Schie RCAA, LaFace DM, Green DR. Early redistribution of plasma membrane phosphatidylserine is fsa general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med. 1995;182:1545-1556.
11. Verhoven B, Schlegel RA, Williamson P. Mechanisms of phosphatidylserine exposure, a phagocyte recognition signal, on apoptotic T lymphocytes. J Exp Med. 1995;182:1597-1601.
12. Aupeix K, Hugel B, Martin T, Bischoff P, Lill H, Pasquali JL, Freyssinet JM. The significance of shed membrane particles during programmed cell death in vitro, and in vivo, in HIV-1 infection. J Clin Invest. 1997;99:1546-1554.
13. Martin SJ, Finucane DM, Amarante-Mendes GP, O'Brien GA, Green DR. Phosphatidylserine externalisation during CD95-induced apoptosis of cells and cytoplasts requires ICE/CED-3 protease activity. J Biol Chem. 1996;271:28753-28756.
14. Luciani M, Chimini G. The ATP binding cassette transporter ABC1, is required for the engulfment of corpses generated by apoptotic cell death. EMBO J. 1996;15:226-235.
15. Savill J. Apoptosis. Phagocytic docking without shocking. Nature. 1998;392:442,443.
16. Madeo F, Frohlich E, Frohlich K. A yeast mutant showing diagnostic markers of early and late apoptosis. J Cell Biol. 1997;139:729-734.
17. Shaham S, Shuman M, Herskowitz I. Death-defying yeast identify novel apoptosis genes. Cell. 1998;92:425-427.
18. MacLellan W, Schneider M. Death by design. Programmed cell death in cardiovascular biology and disease. Circ Res. 1997;81:137-144.
19. Yen E. Life and death in the cardiovascular system. Circulation 1997; 95: 782-786.
20. Schwartz S. Cell death and the caspase cascade. Circulation. 1998;97:227-229.
21. Haunstetter A, Izumo S. Apoptosis: basic mechanisms and implications for cardiovascular disease. Circ Res. 1998;82:1111-1129.
22. Libby P, Geng YJ, Aikawa M, Schoenbeck U, Mach F, Clinton SK, Sukhova GK, Lee RT. Macrophages and atherosclerotic plaque stability. Curr Opin Lipidol. 1996;7:330-335.
23. Kockx MM. Apoptosis in the atherosclerotic plaque. Quantitative and qualitative aspects. Atherosclerosis Thromb Vasc Biol. 1998;18:1519-1522.
24. Chatterjee S. Sphingolipids in atherosclerosis and vascular biology. Arterioscler Thromb Vasc Biol. 1998;18:1523-1533.
25. Bennett MR, Boyle JJ. Apoptosis of vascular smooth muscle cells in atherosclerosis. Atherosclerosis. 1998;138:3-9.
26. Devaux PF. Static and dynamic lipid asymmetry in cell membranes. Biochemistry. 1991;30:1163-1173.
27. Zwaal RFA, Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood. 1997;89:1121-1132.
28. Auland ME, Roufogalis BD, Devaux PF, Zachowski A. Reconstitution of ATP-dependent aminophospholipid translocation in proteoliposomes. Proc Natl Acad Sci USA. 1994-91:10938-10942.
29. Tang X, Halleck MS, Schlegel RA, Williamson P. A subfamily of P-Type ATPases with aminophospholipid transporting activity. Science. 1996;272:1495-1497.
30. Siegmund A, Grant A, Angeletti C, Malone L, Nichols JW, Rudolph HK. Loss of drs2p does not abolish transfer of fluorescence-labeled phospholipids across the plasma membrane of saccharomyces cerevisiae. J Biol Chem. 1998;273:34399-34405.
31. Bratton DL, Fadok VA, Richter DA, Kailey JM, Guthrie LA, Henson PM. Appearance of phosphatidylserine on apoptotic cells requires calcium-mediated nonspecific flip-flop and is enhanced by loss of the aminophospholipid translocase. J Biol Chem. 1997;272:26159-26165.
32. Zhou Q, Zhao J, Stout JG, Luhm RA, Wiedmer T, Sims PJ. Molecular cloning of human plasma membrane phospholipid scramblase. A protein mediating transbilayer movement of plasma membrane phospholipids. J Biol Chem. 1997;272:18240-18244.
33. Kasukabe T, Kobayashi H, Kaneko Y, Okabe-Kado J, Honma Y. Identity of human normal counterpart (MmTRA1b) of mouse leukemogenesis-associated gene (MmTRA1a) product as plasma membrane phospholipid scramblase and chromosome mapping of the human MmTRA1b/phospholipid scramblase gene. Biochem Biophys Res Commun. 1998;249:449-455.
34. Satta N, Toti F, Fressinaud E, Meyer D, Freyssinet JM. Scott syndrome: an inherited defect of the procoagulant activity of platelets. Platelets. 1997;8:117-124.
35. Kalafatis M, Swords N, Rand M, Mann K. Membrane-dependent reactions in blood coagulation: role of the vitamin K-dependent enzyme complexes. Biochim Biophys Acta. 1994;1227:113-129.
36. Fox JE. Shedding of adhesion receptors from the surface of activated platelets. Blood Coagul Fibrinolysis. 1994;5:291-304.
37. Martin SJ, Green DR. Protease activation during apoptosis: death by a thousand cuts? Cell. 1995;82:349-352.
38. Weiss HJ. Scott syndrome: a disorder of platelet coagulant activity. Sem Hematol. 1994;31:312-319.
39. Toti F, Satta N, Fressinaud E, Meyer D, Freyssinet JM. Scott syndrome characterized by impaired transmembrane migration of procoagulant phosphatidylserine and hemorrhagic complications, is an inherited disorder. Blood. 1996;87:1409-1415.
40. Zhou Q, Sims PJ, Wiedmer T. Expression of proteins controlling transbilayer movement of plasma membrane phospholipids in the B lymphocytes from a patient with Scott syndrome. Blood. 1998;92:1707-1712.
41. Janel N, Leroy C, Laude I, Toti F, Fressinaud E, Meyer D, Freyssinet JM, Kerbiriou-Nabias D. Assessment of the expression of candidate human plasma membrane phospholipid scramblase in Scott syndrome cells. Thromb Haemost. 1999;81:322-343.
42. Smit JJM, Schinkel AH, Oude Elferink RPJ, Groen AK, Wagenaar E, van Deemter L, Mol CAAM, Ottenhoff R, van der Lugt NMT, van Roon MA, van der Valk MA, Offerhaus GJA, Berns AJM, Borst P. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell. 1993;75:451-462.
43. Kean LS, Grant AM, Angeletti C, Mahe Y, Kuchler K, Fuller RS, Nichols JW. Plasma membrane translocation of fluorescent-labeled phosphatidylethanolamine is controlled by transcription regulators, PDR1 and PDR3. J Cell Biol. 1997;138:255-270.
44. Toti F, Schindler V, Riou JF, Lombard-Platet G, Fressinaud E, Meyer D, Uzan A, Le Pecq JB, Mandel JL, Freyssinet JM. Another link between phospholipid transmembrane migration and ABC transporter gene family, inferred from a rare inherited disorder of phosphatidylserine externalization. Biochem Biophys Res Commun. 1997;241:548-552.
45. Andree HAM, Reutelingsperger CPM, Hauptmann R, Hemker HC, Hermens WT, Willems GM. Binding of vascular anticoagulant a (VACa) to planar phospholipid bilayers. J Biol Chem. 1990;265:4923-4928.
46. Mosser G, Ravanat C, Freyssinet JM, Brisson A. Sub-domain structure of lipid-bound annexin V resolved by electron image analysis. J Mol Biol. 1991;217:241-245.
47. Ravanat C, Torbet J, Freyssinet JM. A neutron solution scattering study of the structure of annexin V and its binding to lipid vesicles. J Mol Biol. 1992;226:1271-1278.
48. Thiagarajan P, Tait JF. Binding of annexin V/placental anticoagulant protein I to platelets. J Biol Chem. 1990;265:17420-17423.
49. Dachary-Prigent J, Freyssinet JM, Pasquet JM, Carron JC, Nurden AT. Annexin V as a probe of aminophospholipid exposure and platelet membrane vesiculation: a flow cytometry study showing a role for free sulfhydryl groups. Blood. 1993;81:2554-2565.
50. van Heerde WL, de Groot PG, Reutelingsperger CPM. The complexity of the phospholipid binding protein annexin V. Thromb Haemost. 1995;73:172-179.
51. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods. 1995;184:39-51.
52. Pigault C, Follenius-Wund A, Schmutz M, Freyssinet JM, Brisson A. Formation of two-dimensional arrays of annexin V on phosphatidylserine-containing liposomes. J Mol Biol. 1994;236:199-208.
53. Satta N, Toti F, Feugeas O, Bohbot A, Dachary-Prigent J, Eschwège V, Hedman H, Freyssinet JM. Monocyte vesiculation: a mechanism for dissemination of membrane-associated procoagulant activities and adhesion molecules following stimulation by lipopolysaccharide. J Immunol. 1994;153:3245-3255.
54. Kojima H, Newton-Nash D, Weiss HJ, Zhao J, Sims PJ, Wiedmer T. Production and characterization of transformed B-lymphocytes expressing the membrane defect of Scott syndrome. J Clin Invest. 1994;94:2237-2244.
55. Aupeix K, Toti F, Satta N, Bischoff P, Freyssinet JM. Oyxsterols induce membrane procoagulant activity in monocytic THP-1 cells. Biochem J. 1996;314:1027-1033.
56. Bombeli T, Karsan A, Tait JF, Harlan JM. Apoptotic vascular endothelial cells become procoagulant. Blood. 1997;89:2429-2442.
57. Flynn PD, Byrne CD, Baglin TP, Weissberg PL, Bennett MR. Thrombin generation by apoptotic vascular smooth muscle cells. Blood. 1997;89:4378-4384.
58. Kornbluth RS. The immunological potential of apoptotic debris produced by tumor cells and during HIV infection. Immunol Lett. 1994;43:125-132.
59. Casciola-Rosen L, Rosen A, Petri M, Schlissel M. Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus. Proc Natl Acad Sci USA. 1996;93:1624-1629.
60. Bach R, Rifkin DB. Expression of tissue factor procoagulant activity: regulation by cytosolic calcium. Proc Natl Acad Sci USA. 1990;87:6995-6999.
61. Neuenschwander PF, Bianco-Fisher E, Rezaie A, Morrissey JH. Phosphatidylethanolamine augments factor VIIa-tissue factor activity: enhancement of sensitivity to phosphatidylserine. Biochemistry. 1995;34:13988-13993.
62. Fourcade O, Simon MF, Viodé C, Rugani N, Leballe F, Ragad A, Fournié B, Sarda L, Chap H. Secretory phospholipase A2 generates the novel lipid mediator Lysophosphatidic acid in membrane microvesicles shed from activated cells. Cell. 1995;80:919-927.
63. Barry OP, Pratico D, Savani RC, FitzGerald GA. Modulation of monocyte-endothelial cell interactions by platelet microparticles. J Clin Invest. 1998;102:136-144.
64. Tabibzadeh SS, Kong QF, Kapur S. Passive acquisition of leukocyte proteins is associated with changes in phosphorylation of cellular proteins and cell-cell adhesion properties. Am J Pathol. 1994;145:930-940.
65. Albanese J, Meterissian S, Kontogiannea M, Dubreuil C, Hand A, Sorba S, Dainiak N. Biologically active Fas antigen and its cognate ligand are expressed on plasma membrane-derived extracellular vesicles. Blood. 1998;91:3862-3874.
66. Silvestris F, Frassanito MA, Cafforio P, Potenza D, Di Loreto M, Tucci M, Grizzuti MA, Nico B, Dammacco F. Antiphosphatidylserine antibodies in human immunodeficiency virus-1 patients with evidence of T-cell apoptosis and mediate antibody-dependent cellular cytotoxicity. Blood. 1996;87:5185-5195.
67. Triplett DA. Protean clinical presentation of antiphospholipid-protein antibodies (APA). Thromb Haemost. 1995;74:329-337.
68. Bordron A, Dueymes M, Levy Y, Jamin C, Leroy JP, Piette JC, Shoenfeld Y, Youinou PY. The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis. J Clin Invest. 1998;101:2029-2035.
69. Nakamura N, Ban T, Yamaji K, Yoneda Y, Wada Y. Localization of the apoptosis-inducing activity of lupus anticoagulant in an annexin V-binding antibody subset. J Clin Invest. 1998;101:1951-1959.
70. Hörkkö S, Bird DA, Miller E, Itabe H, Leitinger N, Subbanagounder G, Berliner JA, Friedman P, Dennis EA, Curtiss LK, Palinski W, Witztum JL. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest. 1999;103:117-128.
71. Reutelingsperger CP, van Heerde WL. Annexin V, the regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis. Cell Mol Life Sci. 1997;53:527-532.
72. Rand JH, Wu XX, Andree HA, Lockwood CJ, Guller S, Scher J, Harpel PC. Pregnancy loss in the antiphospholipid-antibody syndromea possible thrombogenic mechanism. N Engl J Med. 1997;337:154-160.
73. Hugel B, Socié G, Vu T, Toti F, Gluckman E, Freyssinet JM, Scrobohaci ML. Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. Blood. 1999;93:3451-3456.
74. Mallat Z, Hugel B, Ohan J, Lesèche G, Freyssinet JM, Tedgui A. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques. Circulation. 1999;99:348-353.
75. Mallat Z, Hugel B, Freyssinet JM, Tedgui A. Elevated plasma levels of shed membrane microparticles in patients with acute coronary syndromes. Circulation. 1998;98:I-172a.
76. Mallat Z, Ohan J, Lesèche G, Tedgui A. Colocalization of CPP-32 with apoptotic cells in human atherosclerotic plaques. Circulation. 1997;96:424-428.
77. Steg P, Tahlil O, Aubailly N, Caillaud J, Dedieu J, Berthelot K, Le Roux A, Feldman L, Perricaudet M, Denèfle P, Branellec D. Reduction of restenosis after angioplasty in an atheromatous rabbit model by suicide gene therapy. Circulation. 1997;96:408-411.
78. Sata M, Perlman H, Muruve D, Silver M, Ikebe M, Libermann T, Oettgen P, Walsh K. Fas ligand gene transfer to the vessel wall inhibits neointima formation and overrides the adenovirus-mediated T cell response. Proc Natl Acad Sci USA. 1998:95:1213-1217.
79. Pollman M, Hall J, Mann M, Zhang L, Gibbons G. Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease. Nat Med. 1998;4:222-227.
80. Giesen PA, Rauch U, Bohrmann B, Kling D, Roqué M, Fallon JT, Badimon JJ, Himber J, Riederer MA, Nemerson Y. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA. 1999;96:2311-2315.
81. Ross R. Mechanisms of Disease: Atherosclerosis - An inflammatory disease. N Engl J Med. 1999;340:115-126.
82. Best PJ, Hasdai D, Sangiorgi G, Schwartz RS, Holmes DR Jr, Simari RD, Lerman A. Apoptosis: Basic concepts and implications in coronary artery disease. Arterioscler Thromb Vasc Biol. 1999;19:14-22.
83. Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, Mangion J, Jacotot E, Costantini P, Loeffler M, Larochette N, Goodlett DR, Aebersold R, Siderovski DP, Penninger JM, Kroemer G. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature. 1999;397:441-446.
84. c+ membrane particles in a human T lymphocyte model. J Immunol. 1999;162:5712-5718.